// STATE LEGISLATION TRACKER

Illinois HB 4954: 340B PRICING PROGRAM REPORT

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Illinois
Bill: HB 4954
Session: 104th
Filed: 2026-02-04
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

HB4954 creates reporting requirements for Illinois entities that participate in the federal 340B drug discount program. It does not appear to regulate compounded peptides, off-label prescribing, telehealth, NP or naturopath scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to access for compounded peptides
No new limits on off-label prescribing are indicated
No telehealth, NP, or naturopath scope change is indicated
No 503A or 503B compounding change is indicated
340B entities would face added reporting duties

What to Watch For

Note The bill is about 340B drug-pricing transparency, not peptide prescribing or compounding.

Concern Covered clinics or hospitals using 340B could face extra reporting burden and penalties.

Note Any peptide impact would likely be indirect and only through 340B-participating care settings.

Where the Bill Stands

The bill has been introduced in the Illinois House process, with no chamber passage indicated.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws